IMPORTANCE Both dietary modification and use of statins can lower blood cholesterol. The increase in caloric intake among the general population is reported to have plateaued in the last decade, but no study has examined the relationship between the time trends of caloric intake and statin use.
amined whether the temporal trend in food intake is related to statin use, although previous studies have investigated the cross-sectional and short-term relationship between statin use and food intake. [10] [11] [12] In this context, we examined whether the time trends of caloric and fat intake differed between statin users and nonusers.
Methods

Data Sources and Study Population
This is a repeated cross-sectional study using data from the National Health and Nutrition Examination Survey (NHANES), 1999 through 2010. 13 Written informed consent was obtained from all participants. The NCHS Research Ethics Review Board approved the NHANES protocols.
14 NHANES is conducted by the National Center for Health Statistics (NCHS) at the Centers for Disease Control and Prevention. It uses a stratified, multistage probability sampling design, which enables samples to represent the US civilian noninstitutionalized population. 13 Data are collected at their homes and mobile examination centers (MECs). Among adults in NHANES during the 1999-2010 period, the unweighted response rate for the household interview was 74.8%; that for the MEC examination was 70.8%.
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This study included data from individuals 20 years or older. Since pregnancy is a contraindication to statin use, we excluded pregnant women from our analyses (n = 1294), which resulted in a sample of 31 170. In the main analysis, we also excluded those with missing information on in-person dietary interview (n = 3210), statin use (n = 13), and potential confounders of our analyses (n = 61), which produced a final sample of 27 886.
Food Intake
During the MEC examination, trained interviewers conducted a 24-hour dietary recall interview and obtained dietary data on the last day before the interview. For the 1999-2001 survey period, dietary interviews were conducted using a computer-assisted automated data collection system with a multiple pass format. 16 , and their nutrient components were analyzed. For this study, we extracted data on total caloric intake and total fat intake as the primary outcome variables. We also extracted data on saturated fat intake and dietary cholesterol intake for additional analyses.
Cholesterol Levels and BMI
As secondary outcome variables, we extracted data on serum levels of total cholesterol and low-density lipoprotein cholesterol (LDL-C), and body mass index (BMI, calculated as weight in kilograms divided by height in meters squared). Blood specimens were collected during the MEC examination. Levels of LDL-C were calculated using the Friedewald equation 19 (total cholesterol − high-density lipoprotein cholesterol − triglycerides/5) for participants examined in the morning in their fasting states with triglyceride levels of 400 mg/dL or lower (to convert triglycerides to millimoles per liter, multiply by 0.0113). Sample size was reduced by 54% when we used fasting values, and sampling weight for fasting blood-sampling examinees prepared by NHANES was used to estimate the entire population parameters. Height and weight were measured during the MEC examination.
Hyperlipidemia and Statin Use
We defined hyperlipidemia as either self-reported diagnosis of hyperlipidemia (diagnosed and reported to the participant by a health care professional) or as documentation that the participant was taking medications for hyperlipidemia (statins and others). We did not use the measurements of cholesterol or fat for our definition of hyperlipidemia in this study. That is, we classified individuals with hyperlipidemia who were undiagnosed as not having hyperlipidemia. The rationale was that those who did not know their hyperlipidemia diagnosis would not modify their diets. Statin use was defined on the basis of interviewerconfirmed medication containers matched to a comprehensive prescription drug database (Lexicon Plus). 13 We identified 7 types of statin ingredients prescribed for NHANES participants: lovastatin, simvastatin, pravastatin, fluvastatin, atorvastatin, cerivastatin, and rosuvastatin. Statin use was defined whether the statin ingredient came from a separate pill or a fixed-dose combination. We divided participants into statin users and nonusers. Statin nonusers included those without hyperlipidemia and those with hyperlipidemia but not receiving statins.
Potential Confounders
We extracted data on potential confounders including age, sex, race and ethnicity, educational attainment, and the diagnosis of diabetes. We categorized age into 3 groups: 20 to 39 years, 40 to 59 years, and 60 years or older. Race and ethnicity were classified into non-Hispanic white, non-Hispanic black, Mexican American, and others including other Hispanics and multiracial participants. We categorized educational attainment into greater than high school, high school graduation or Gen-
Statistical Analysis
All statistical analyses were conducted using Stata (version 12.1; StataCorp LP), accounting for the complex survey design. Taylor series linearization was used for variance estimation. 20 We used an appropriate weight for each analysis selected based on the variables in the analysis. These weights accounted for unequal probabilities of selection and nonresponses to make unbiased national estimates. To conduct trend analyses, we combined 6 cycles of NHANES data (1999-2000 through 2009-2010) .
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Proportion of statin use was calculated for each survey cycle. Descriptive statistics for patients' characteristics were calculated separately for statin users and nonusers. Linear trends over time were assessed based on χ 2 tests for categorical variables and linear regressions for continuous variables. We compared the characteristics between the groups using pooled samples across the study period. We also investigated whether time trends of cholesterol levels and BMI differed by group using models including interaction terms between survey cycle and statin use. Next, we developed regression models to evaluate temporal time trends of caloric and fat intake separately for statin users and nonusers and to examine whether trends for caloric and fat intake differed by statin use. We used generalized linear models (GLMs) with log-link function to take into account the rightskewed distributions of the intake. The results of the Park test 22 indicated a γ-distribution as the most appropriate distribution for our data. We included interaction terms between survey cycle (categorical) and statin use (binary) to allow nonlinear time trends to be different by statin use. We also included age category, sex, race and ethnicity, educational attainment, and diabetes diagnosis for adjustment. We applied these models to calculate model-adjusted estimates of caloric and fat intake per day for each combination of statin use and survey cycle and tested the differences of caloric and fat intake by statin use within each survey cycle. We then calculated separately for statin users and nonusers the adjusted percentage changes of caloric and fat intake in each survey cycle, setting the 1999-2000 period as the reference cycle separately for statin users and nonusers. Linear time trend was used to approximate the change over the study period, and the significance tests of the interaction term between survey cycle (continuous) and statin use (binary) was performed to examine the difference in trends of intake between statin users and nonusers.
As additional analyses, we divided statin nonusers into those with and without a diagnosis of hyperlipidemia and compared the time trends of 3 groups. Moreover, we performed additional sensitivity analyses; we made trend graphs of caloric and fat intake estimates restricted to those who did not have diabetes diagnoses.
We also performed additional regression analyses to evaluate the temporal trends of saturated fat and dietary cholesterol intake separately for statin users and nonusers.
We also created GLMs for BMI, total cholesterol level, and LDL-C level. In the models, we controlled for age category, sex, race and ethnicity, and education attainment. The results of the Park test 22 indicated that a γ-distribution was the most appropriate for BMI, whereas a Poisson distribution was the most suitable for cholesterol levels. We included interaction terms between survey cycle (categorical) and statin use (binary), and we applied these models to calculate model-adjusted estimates of BMI, total cholesterol level, and LDL-C level for each combination of statin use and survey cycle. By creating additional models with a continuous survey cycle variable, we examined the differences in trends by statin use.
Results
The proportion of statin users from the NHANES 1999-2010 study population in our sample more than doubled from 7.5% to 16.5% over the decade of observation ( Table 1 ) (eTable in the Supplement). We divided statin nonusers into those with and without hyperlipidemia and found that the proportion of the population who were nonusers without hyperlipidemia decreased from 74.6% to 67.8% (P < .001), whereas the proportion of the population who were nonusers with hyperlipidemia did not change significantly (P = .14) (eTable in the Supplement). We found time trends toward a smaller proportion of white race and a larger proportion of black race among statin users and a trend toward higher educational attainment among both groups. Diabetes diagnosis became more prevalent among statin users. Statin users were more likely to be older, male, white, less educated, have diagnosis of diabetes, and have higher BMI. Between the 1999-2000 and 2009-2010 periods, BMI increased by 1.3 among statin users compared with a 0.5 increase in nonusers (P = .02 for difference in trends), while the decrease of total cholesterol between statin users in the same period was greater than that among nonusers (from 201.9 to 178.1 mg/dL for statin users and from 203.6 to 199.6 mg/dL for nonusers) (P < .001 for difference in trends). Findings were similar for LDL-C levels. (To convert total cholesterol and LDL-C to millimoles per liter, multiply by 0.0259.) Table 2 and Figure 1 and When we tested time trends of caloric intake separately for statin users and nonusers (Table 3) , among statin users, we found an increase in caloric intake during the study period: the caloric intake among statin users in the 2009-2010 period was 9.6% greater (95% CI, 1.8-18.1; P = .02) than that among statin The interactions between survey cycle and statin use were significant in the models with a continuous survey cycle variable (P = .001 for caloric intake and P < .001 for fat intake), which indicates that time trends for caloric and fat intake in the 2 groups were significantly different. eFigures 1 and 2 in the Supplement present the results of the additional analyses stratifying statin nonusers into those with and without hyperlipidemia, comparing 3 groups in total. As a result, both nonuser groups (those with and without hyperlipidemia) had similar time trends of caloric intake (upward in the earlier survey cycles and downward in the later survey cycles), whereas the trend among statin users was consistently upward. The difference of the trends for caloric and fat intake between statin users and nonusers with hyperlipidemia was significant (P = .02 for caloric intake and P = .01 for fat intake). To determine if the findings were driven by increased prevalence of diabetes, we examined time trends in caloric and fat intake in those without diabetes; time trends were similar to those for the entire sample (eFigures 3 and 4 in the Supplement).
In the additional time trend analyses, we found similar patterns for saturated fat and dietary cholesterol intake (eFigures 5 and 6 in the Supplement). The interaction term was sig- nificant for saturated fat intake (P < .001) but not for dietary cholesterol intake (P = .09). The trends of model-estimated BMI revealed a 1.3 (95% CI, 0.5-2.1; P = .001) increase among statin users and a 0.4 (95% CI, −0.1 to 1.0; P = .10) increase among nonusers during the study period (eFigure 7 in the Supplement). The test for interaction effects revealed a faster increase of BMI for statin users (P = .03), although the increasing trends were significant for both statin users (P < .001) and nonusers (P = . 
Discussion
In the 1999-2000 period, statin users consumed fewer calories and less fat than nonusers, as we would expect in persons attempting to control their cholesterol level and weight. During the ensuing decade, statin use expanded rapidly, and statin users consumed more calories and fat than earlier cohorts, which was not true for nonusers. As a result, differences in intake between statin users and nonusers disappeared by the 2005-2006 period for caloric intake and by the 2003-2004 period for fat intake. This difference in the time trends for caloric and fat intake between statin users and nonusers was not explained by presence or absence of diagnoses of hyperlipidemia in nonusers or higher prevalence of diabetes among statin users.
To the best of our knowledge, this is the first study showing that time trends for caloric and fat intake differ by statin use in the United States. A cross-sectional study in early 2000s in Rhode Island found that statin use was associated with an insignificant decrease in caloric intake among older adults. 10 Another cross-sectional study in 2004 in Sweden found that statin-using adults were more likely to avoid food with high fat content than nonusers. 11 These results were consistent with our findings from earlier survey cycles that statin users had less caloric and fat intake than nonusers. A cohort study in Veterans Affairs primary care clinics observed newly prescribed statin users for 6 months in 2005 and found no increase in caloric and fat intake. 12 Although that longitudinal study design allowed stronger causal inference, 6 months may be too short to conclude that statin use is not associated with dietary laxity. We used cross-sectional data collected over 12 years that allowed us to see the trends of caloric and fat intake during the time when statin prescription rapidly increased. What are the implications of the observed change in caloric intake among statin users in terms of effect size and relationship with dietary recommendations in the guideline? Given that 7000 kcal extra caloric imbalance is estimated to induce 1 kg weight gain in an adult, 23 the estimated 192 kcal/d increase among statin users could have contributed to the observed 1.3 increase in BMI (equivalent to a 3-to 5-kg weight gain) over a decade. Since the guideline recommends that patients should prevent weight gain, 3 the observed increase in caloric intake and more rapid increase in BMI among statin users are of concern. According to the guidelines, people who receive statin therapy also should take steps to reduce fat intake, 3,5 but
we did not observe a pattern of combining statin use with dietary control. The observed 14.4% increase in fat intake was greater than overall increase in caloric intake (9.6%). While the proportion of calories from fat did not exceed the upper limit of the recommended range (25%-35%), 3 the extreme, if statin users became less likely to hesitate to reveal their true intake, our observations might not reflect true change in diet. However, the magnitude of our findings may be too large to be explained only by changes attributable to social desirability bias. Second, our data are a serial cross-section in which participants change from one panel to the other rather than cohort data in which same individuals are examined repeatedly. Therefore, we cannot infer that a particular individual who took statins throughout the study period consumed more calories and fat in recent years than a decade ago. However, given that the sampling weights of the NHANES allow us to make national estimates, we reasonably can conclude that an average American treated with statin in the 2009-2010 period consumed more calories and fat compared than an average American taking statin in the 1999-2000 period. We can only speculate on the mechanisms behind the observed trends: one possibility is that statin use may have undermined the perceived need to follow dietary recommendations. Patients who recognized that their LDL-C levels were lowered drastically by statins may have lost the incentive to pursue dietary modifications. Physicians might have contributed to this process by shifting the focus of consultations from diet to statin regimen adherence once statin treatment had begun. This hypothesis is compatible with the lower cholesterol levels seen among statin users than among nonusers in later survey cycles (Table 1) .
Another possible mechanism is that expanded statin use occurred in people who were likely to eat more. Some patients may have agreed to initiate statin therapy because they did not want to restrict their diet, whereas others who did not want to take medication may have declined the proposed pharmacotherapy in favor of following dietary recommendations. We adjusted for differences in characteristics among statin users across survey cycles in the models but did not adjust for cholesterol levels and BMI because they could have been consequences of food intake.
As to physical activity, NHANES measured it, but we did not include it in the main analyses owing to inconsistent measurement: it changed between the 2005-2006 and 2007-2008 periods. As a sensitivity analysis, we included a physical activity variable in spite of the inconsistency, which did not change the results.
However, other unmeasured factors may have affected the findings. For example, it is possible that those participants taking statins in the early survey cycles exhibited more severe hyperlipidemia, while those with less severe hyperlipidemia initiated statin treatment in later cycles as their use increased. The greater decrease of cholesterol levels among statin users over time may be partially explained by expanded therapeutic use.
Our study design precluded evaluation of the extent to which these scenarios explain the findings. A cohort study with sufficiently long follow-up could address these questions.
Conclusions
Whatever the mechanism, our results indicate that caloric and fat intake among statin users in the 2009-2010 period was significantly greater than they were in the 1999-2000 period. We may need to reemphasize the importance of dietary modification for statin users.
At the same time, it may be appropriate to reevaluate and discuss dietary recommendations in the time of statins. The recently published ACC/AHA guideline emphasized extensive statin use for patients who are likely to experience a net benefit 5 ; statin use is predicted to expand further if practitioners follow the guideline. 25 Although the guideline articulates that lifestyle modification remains the foundation for cardiovascular disease risk reduction, 5 further expansion of statin use may result in more statin users not following dietary recommendations (extrapolating from our study results). From the perspective of effectiveness, although the additional effects of low-fat diet on lowering LDL-C level among statin users have been shown, 26,27 the incremental benefit of low-fat diet on cardiovascular disease prevention among those taking statins has not been fully investigated. Moreover, costeffectiveness and ethical considerations should be taken into account. Particularly in a time when obesity and diabetes have become epidemics and US health care costs have been soaring, we need to consider if it is an acceptable public health strategy to encourage statin use without also taking measures to decrease the likelihood that its use will be associated with increased caloric and fat intake as well as weight gain. We believe that the goal of statin treatment, as with any pharmacotherapy, should be to allow patients to decrease risks that cannot be decreased without medication, not to empower them to put butter on their steaks.
